Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arrowhead Pharmaceuticals, Inc. - Common Stock
(NQ:
ARWR
)
65.14
-1.09 (-1.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arrowhead Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Arrowhead (ARWR) Q3 2025 Earnings Call Transcript
↗
August 07, 2025
Via
The Motley Fool
Topics
Earnings
Arrowhead (ARWR) Q3 Revenue Drops 41%
↗
August 07, 2025
Via
The Motley Fool
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Mixed Q3 2025 Results with Revenue Beat but Wider-Than-Expected Loss
↗
August 07, 2025
Arrowhead Pharmaceuticals reported mixed Q3 2025 results, beating revenue estimates but missing on EPS. Stock fell 5.3% as higher R&D costs widened losses. Key pipeline updates include plozasiran NDA...
Via
Chartmill
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
August 07, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement
↗
July 23, 2025
Via
Stocktwits
Earnings Scheduled For May 12, 2025
↗
May 12, 2025
Via
Benzinga
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
August 01, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On?
↗
July 29, 2025
Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys,...
Via
Benzinga
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
↗
July 28, 2025
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.
Via
Benzinga
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
July 28, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
↗
July 25, 2025
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.
Via
Benzinga
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
↗
July 25, 2025
Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys.
Via
Investor's Business Daily
Topics
Death
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 24, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
↗
July 23, 2025
Via
Benzinga
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
July 23, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review
↗
July 22, 2025
Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter.
Via
Benzinga
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
July 21, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
July 08, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
June 23, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'
↗
June 04, 2025
Arrowhead Pharmaceuticals, Snowflake, Dover and Fluor are each in focus on today's edition of "Mad Money Lightning Round."
Via
Benzinga
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
June 02, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
May 29, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Archer Aviation Posts Narrower-Than-Expected Loss, Joins Microvast, Intuitive Machines And Other Big Stocks Moving Higher On Tuesday
↗
May 13, 2025
Via
Benzinga
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
↗
May 13, 2025
Via
Benzinga
Which stocks are moving after the closing bell on Monday?
↗
May 12, 2025
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
May 12, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Insights Ahead: Arrowhead Pharma's Quarterly Earnings
↗
May 09, 2025
Via
Benzinga
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
May 07, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results
April 30, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
